Research shows that cancer death rates are dropping across the country

AN ANTONIO – Cancer death rates are dropping across the country, according to the American Association for Cancer Research. There are more than 18 million cancer survivors in the U.S., proving that more people are living longer, fuller lives after being diagnosed. Doctors say new treatments, diagnostic tools, and prevention strategies have helped with the decline in deaths. Dr. Anthony …

Alexander I. Spira, MD, PhD, FACP, Provides an Overview of the Use of Adagrasib in Advanced KRAS G12C–Mutant NSCLC at ASCO 2022

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Annual Meeting, Alexander I. Spira, MD, PhD, FACP, a medical oncologist and co-director of the Virginia Cancer Specialists Research Institution, and director of the Thoracic and Phase I Program and clinical assistant professor at Johns Hopkin, discusses the safety profile of adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C–mutated non–small cell …

DCC-3116 Acceptable Treatment in RAS/RAF-Mutant Solid Tumors

A phase 1/2 trial (NCT04892017) found a potential treatment with DCC-3116 monotherapy given between 50 mg to 300 mg twice daily for patients with RAS or RAF-mutant solid tumors, based on a presentation from the 2022 European Society for Medical Oncology Congress. At the June 9, 2022, data cutoff, no dose-limiting toxicities or serious treatment-emergent adverse effects (TEAEs) were reported. Additionally, …

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has formed a Scientific Advisory Board (SAB) in support of the development of its lead therapeutic candidate QN-302 for the …

Valentina Boni, MD, PhD, Talks Safety of Lurbinectedin Monotherapy in Pretreated BRCA-Associated Advanced Breast Cancer

Valentina Boni, MD, PhD, of the Early Drug Development Unit at the Universitary Hospital Universitario Quirónsalud Madrid as well as director and principal investigator at NEXT Oncology Madrid in Spain, spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about lurbinectedin (Zepzelca) monotherapy for patients with BRCA1/2-associated metastatic breast cancer, which was examined in a phase 2 basket study …

SA cancer research group ramping up Spain expansion

San Antonio has a deep bench and long history in cancer research, and it’s expanding on that expertise and infrastructure on multiple fronts, drawing more talent and investment to back that growth. This spring, San Antonio-based NEXT Oncology launched operations in Spain with an early-phase clinical trial in Madrid. It’s part of a growth plan founder Dr. Anthony Tolcher outlined …

Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset

When given as a single-agent (not with any other drugs), adagrasib led to promising outcomes for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to results from part of the phase 1/2 KRYSTAL-1 clinical trial that were presented at the 2022 American Society of Clinical Oncology Annual Meeting. At the meeting, Dr. Alexander I. Spira, co-director of Virginia Cancer …

NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center

When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer (TNBC) with an anti-drug conjugate used in …